Adverum Biotechnologies Inc
ADVM2.510USD
+0.190+8.19%
收盘 08/04, 16:00（美东）报价延迟15分钟
52.10M总市值
亏损市盈率 TTM
关于 Adverum Biotechnologies Inc 公司
Adverum Biotechnologies, Inc. 是一家临床阶段的基因治疗公司。该公司发现并开发基因治疗候选产品，通过诱导治疗性蛋白质的持续表达来提供持久的疗效。其主要候选产品 ixoberogene soroparvovec (Ixo-vec) 是一种单次、办公室内玻璃体内 (IVT) 注射基因治疗产品，旨在提供与持续治疗反应相关的长期持久的阿柏西普水平，减少治疗负担和与频繁抗血管内皮生长因子 (VEGF) IVT 注射相关的黄斑液波动。Ixo-vec 正在开发用于治疗湿性老年性黄斑变性患者。其第二个候选产品 ADVM-062 (AAV.7m8-L-opsin) 是一种基因治疗候选产品，正在开发中，通过单次 IVT 注射治疗患有蓝锥单色性 (BCM) 的患者。该公司还正在开发早期的基因治疗项目。
公司简介
公司代码ADVM
公司名称Adverum Biotechnologies Inc
上市日期Jul 31, 2014
CEODr. Laurent Fischer, M.D.
员工数量155
证券类型Ordinary Share
年结日Jul 31
公司地址100 Cardinal Way
城市REDWOOD CITY
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94063
电话16506491004
网址https://adverum.com/
公司代码ADVM
上市日期Jul 31, 2014
CEODr. Laurent Fischer, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Ms. Linda M. Rubinstein
Ms. Linda M. Rubinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason L. Mitchell
Mr. Jason L. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
持股股东
持股股东
占比
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
股东类型
持股股东
占比
Investment Advisor
46.39%
Investment Advisor/Hedge Fund
15.91%
Individual Investor
12.20%
Private Equity
6.88%
Venture Capital
5.02%
Hedge Fund
2.57%
Research Firm
2.54%
Corporation
0.87%
Bank and Trust
0.12%
Other
7.51%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
192
19.32M
92.50%
-3.22M
2025Q1
200
18.99M
90.93%
-3.09M
2024Q4
197
18.17M
87.35%
-2.16M
2024Q3
205
18.40M
88.51%
-3.17M
2024Q2
198
18.25M
87.99%
-2.40M
2024Q1
209
17.03M
82.27%
+429.10K
2023Q4
203
6.60M
65.29%
-2.40M
2023Q3
243
6.95M
68.86%
-2.49M
2023Q2
271
6.98M
69.47%
-2.29M
2023Q1
309
6.72M
66.88%
-3.80M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BML Capital Management LLC
3.06M
14.64%
+315.21K
+11.49%
May 19, 2025
TCG Crossover Management, LLC
1.80M
8.6%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.76M
8.43%
--
--
Mar 31, 2025
Principia Wealth Advisory, LLC
1.70M
8.12%
+366.15K
+27.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.31M
6.29%
-57.92K
-4.22%
Mar 31, 2025
Stern (Augustus)
1.12M
5.35%
+1.12M
--
Oct 29, 2024
Frazier Life Sciences Management, L.P.
1.07M
5.12%
--
--
Mar 31, 2025
Rush (Ryan Bradford)
1.05M
5.03%
+1.05M
--
Dec 17, 2024
The Vanguard Group, Inc.
1.03M
4.93%
-1.76K
-0.17%
Mar 31, 2025
5AM Ventures
541.67K
2.59%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
iShares Micro-Cap ETF
占比0.01%
Fidelity Enhanced Small Cap ETF
占比0%
iShares Russell 2000 ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Global X Russell 2000 ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
ProShares Hedge Replication ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Dimensional US Core Equity 1 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
公告日期
类型
比率
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
